ELDN

Eledon Pharmaceuticals, Inc.

2.95 USD
+0.22 (+8.06%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Eledon Pharmaceuticals, Inc. stock is up 2.08% since 30 days ago. The next earnings date is Aug 8, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 20% of the previous 9 June’s closed higher than May. 100% of analysts rate it a buy.

About Eledon Pharmaceuticals, Inc.

Eledon Pharmaceuticals, Inc. focuses on developing medicines for the patients living with autoimmune disease and amyotrophic lateral sclerosis. Its lead product candidate includes AT-1501, a humanized monoclonal antibody to target CD40 Ligand that is a molecule expressed on the surface of human immune system T cells, which is in Phase 2a clinical trials for the treatment of ALS.